Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7795081 in Chinese Adult Participants With Obesity or Overweight
NCT07499050Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing RO7795081 with Placebo (2 arms). Primary endpoints: Incidence, Severity, and Causal Relationship to Treatment of Adverse Events at 26 weeks, Incidence of Abnormal Clinical Laboratory Test Findings at 26 weeks and 3 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
RO7795081
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07499050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07499050.